Growth hormone therapy in adults and children

New England Journal of Medicine

Volumn 341, Issue 16, 1999, Pages 1206-1216

  Vance, Mary Lee ^a   Mauras, Nelly ^b  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^b NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ARTHRALGIA; CHRONIC KIDNEY FAILURE; DRUG INDICATION; EDEMA; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HORMONE RESPONSE; HUMAN; MYALGIA; PRIORITY JOURNAL; REVIEW; SHORT STATURE; TURNER SYNDROME;

ADULT; CHILD; GROWTH DISORDERS; HIV WASTING SYNDROME; HUMAN GROWTH HORMONE; HUMANS; KIDNEY FAILURE, CHRONIC; TURNER SYNDROME;

EID: 0033554708     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199910143411607     Document Type: Review

References (99)

1. Attanasio AF, Lamberts SWJ, Matranga AMC, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997;82:82-8.
2. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;83:379-81.
3. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KKY. Diagnosis of growth-hormone deficiency in adults. Lancet 1994;343:1064-8. [Erratum, Lancet 1994;344:206.]
4. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-8.
5. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169-72.
6. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46:75-81.
7. Rutherford OM, Jones DA, Round JM, Preece MA. Changes in skeletal muscle after discontinuation of growth hormone treatment in young adults with hypopituitarism. Acta Paediatr Scand Suppl 1989;356:61-3.
8. Cuneo RC, Salomon F, Wiles CM, Sonksen PH. Skeletal muscle performance in adults with growth hormone deficiency. Horm Res 1990;33: Suppl 4:55-60.
9. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sönksen PH. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 1991;70:695-700.
10. Lehmann ED, Hopkins KD, Weissberger AJ, Gosling RG, Sonksen PH. Aortic distensibility in growth hormone deficient adults. Lancet 1993; 341:309.
11. Bing-You RG, Denis M-C, Rosen CJ. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcif Tissue Int 1993;52:183-7.
12. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992;340:1188-92.
13. Cuneo RC, Salomon F, Watts GF, Hesp R, Sonksen PH. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993;42:1519-23.
14. Merola B, Cittadini A, Colao A, et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993;77:1658-61.
15. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78:669-74.
16. Nass R, Huber RM, Klauss V, Muller OA, Schopohl J, Strasburger CJ. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995;80:552-7.
17. Longobardi S, Cuocolo A, Merola B, et al. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin Endocrinol (Oxf) 1998;48:137-43.
18. Binnerts A, Deurenberg P, Swart GR, Wilson JHP, Lamberts SWJ. Body composition in growth hormone-deficient adults. Am J Clin Nutr 1992;55:918-23.
19. Rosen T, Johannsson G, Hallgren P, Caidahl K, Bosaeus I, Bengtsson BA. Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinol Metab 1994;1:55-66.
20. de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995;16:63-86.
21. McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl 1989;356:70-2.
22. Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 1994;40:111-6.
23. Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321:1797-803.
24. Jorgensen JOL, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;1:1221-5.
25. Whitehead HM, Boreham C, McIlrath EM, et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 1992;36:45-52.
26. Bengtsson BA, Eden S, Lönn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76:309-17.
27. O'Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993;76:1344-8.
28. Mardh G, Lundin K, Borg G, Jonsson B, Lindeberg A. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol Metab 1994;1:Suppl A:43-9.
29. Hansen TB, Vahl N, Jorgensen JOL, Christiansen JS, Hagen C. Whole body and regional soft tissue changes in growth hormone deficient adults after one year of growth hormone treatment: a double-blind, randomized, placebo-controlled study. Clin Endocrinol (Oxf) 1995;43:689-96.
30. Beshyah SA, Henderson A, Niththyananthan R, et al. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 1995;80:356-63.
31. Baum HBA, Biller BMK, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency: a randomized, placebo-controlled trial. Ann Intern Med 1996;125:883-90.
32. Al-Shoumer KAS, Page B, Thomas E, Murphy M, Beshyah SA, Johnston DG. Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults. Eur J Endocrinol 1996;135:559-67.
33. Cuneo RC, Judd S, Wallace JD, et al. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Mctab 1998;83:107-16.
34. Jorgensen JOL, Pedersen SA, Thuesen L, et al. Long-term growth hormone treatment in growth hormone deficient adults. Acta Endocrinol (Copenh) 1991;125:449-53.
35. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonkscn PH. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991;70:688-94.
36. Jorgensen JOL, Thuesen L, Muller J, Ovesen P, Skakkebaek NE, Christiansen JS. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol 1994;130:224-8.
37. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993;77:1671-6.
38. Jorgensen JOL, Vahl N, Nyholm B, et al. Substrate metabolism and insulin sensitivity following long-term growth hormone (GH) replacement therapy in GH-deficient adults. Endocrinol Metab 1996;3:281-6.
39. Snel YEM, Doerga ME, Brummer RJM, Zelissen PMJ, Zonderland ML, Koppeschaar HPF. Resting metabolic rate, body composition and related hormonal parameters in growth hormone-deficient adults before and after growth hormone replacement therapy, Eur J Endocrinol 1995;133: 445-50.
40. Takala J, Ruokoncn E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785-92.
41. Rose SR, Ross JL, Uriarte M, Barnes KM, Cassorla FG, Cutler GB Jr. The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. N Engl J Med 1988;319:201-7.
42. Guidelines for the use of growth hormone in children with short stature: a report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. J Pediatr 1995;127:857-67.
43. Celnikcr AC, Chen AB, Wert RM Jr, Sherman BM. Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989;68:469-76.
44. Smith WJ, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR. Use of insulin-like growth factor-binding protein-2 (IGFBP2), IGFBP3, and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 1993;77:1294-9.
45. Primary IGF-I deficiency due to primary growth hormone resistance (Laron syndrome). In: Merimee TJ, Laron Z. Growth hormone, IGF-I and growth: new views of old concepts. Vol. 4 of Modern endocrinology and diabetes. London: Freund Publishing, 1996.
46. Attie KM, Carlsson LMS, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature: the National Cooperative Growth Study. J Pediatr 1995;127:244-50.
47. Goddard AD, Covello R, Luoh S-M, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. N Engl J Med 1995;333:1093-8.
48. Nishi Y, Masuda H, Nishimura S, et al. Isolated human growth hormone deficiency due to the hGH-I gene deletion with (type IA) and without (the Israeli-type) hGH antibody formation during hGH therapy. Acta Endocrinol (Copenh) 1990;122:267-71.
49. Cogan JD, Phillips JA III, Schcnkman SS, Milner RD, Sakati N. Familial growth hormone deficiency: a model of dominant and recessive mutations affecting a monomeric protein. J Clin Endocrinol Metab 1994;79: 1261-5.
50. Phillips JA III. Regulation and defects in expression of growth hormone genes. In: Isaksson O, Binder C, Hall K, Hokfeld B, eds. Growth hormone: basic and clinical aspects. Amsterdam: Excerpta Medica, 1987: 11-27.
51. Parks JS, Kinoshita E, Pfäffle RW. Pit-1 and hypopituitarism. Trends Endocrinol Metab 1993;4:81-5.
52. Pfäffle RW, DiMattia GE, Parks JS, et al. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992;257:1118-21.
53. Tatsumi K, Miyai K, Notomi T, et al. Cretinism with combined hormone deficiency caused by a mutation in the PITI gene. Nat Genet 1992; 1:56-8.
54. Radovick S, Nations M, Du Y, Berg LA, Weintraub BD, Wondisford FE. A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 1992;257:1115-8.
55. Ohta K, Nobukuni Y, Mitsubuchi H, et al. Mutations in the Pit-1 gene in children with combined pituitary hormone deficiency. Biochem Biophys Res Commun 1992;189:851-5.
56. Wu W, Cogan JD, Pfäffle RW, et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 1998;18:147-9.
57. Baumann G, Maheshwari H, The dwarfs in Sindh: severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. Acta Paediatr Suppl 1997;423:33-8.
58. Takahashi Y, Kaji H, Okimura Y, Goji K, Abe H, Chihara K. Short stature caused by a mutant growth hormone. N Engl J Med 1996;334: 432-6. [Erratum, N Engl J Med 1996;334:1207.]
59. Haddad SF, VanGilder JC, Menezes AH. Pediatric pituitary tumors. Neurosurgery 1991;29:509-14.
60. Clayton PE, Shalet SM. Dose dependency of time of onset of radiation-induced growth hormone deficiency. J Pediatr 1991;118:226-8.
61. Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child 1985;60:932-5.
62. Lippe B, Plotnick L, Attie K, Frane J. Growth in Turner syndrome: updating the United States experience. In Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome. Amsterdam: Excerpta Medica, 1993: 77-82.
63. Maes M, Lindberg A, Price DA, Albertsson Wikland K, Ranke MB. Long term growth response to growth hormone therapy in prepubertal children with idiopathic growth hormone deficiencies: analysis of Kabi International Growth Study. In: Kabi International Growth Study biannual report. No. 11. Mannheim, Germany: J.&J. Verlag, 1994:15-26.
64. Blethen SL, Baptista J, Kuntze J, Foley T, LaFranchi S, Johanson A. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. J Clin Endocrinol Metab 1997;82:418-20.
65. MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. J Clin Endocrinol Metab 1996;81:1806-9.
66. Mauras N, Blizzard RM, Link K, Johnson ML, Rogol AD, Veldhuis JD. Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon. J Clin Endocrinol Metab 1987;64:596-601.
67. Martha PM Jr, Gorman KM, Blizzard RM, Rogol AD, Veldhuis JD. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab 1992;74:336-44.
68. Veldhuis JD. New modalities for understanding dynamic regulation of the somatotropic (GH) axis: explication of gender differences in GH neuroregulation in the human. J Pediatr Endocrinol Metab 1996;9:Suppl 3: 237-53.
69. Stanhope R, Uruena M, Hindmarsh P, Leiper AD, Brook CGD. Management of growth hormone deficiency through puberty. Acta Paediatr Scand Suppl 1991;372:47-52.
70. Fine RN, Kohaut EC, Brown D, Perlman AJ. Growth after rccombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. J Pediatr 1994;124:374-82.
71. Tönshoff B, Dietz M, Haffner D, Tönshoff C, Stöver V, Mehls O. Effects of two years of growth hormone treatment in short children with renal disease. Acta Paediatr Scand Suppl 1991;379:33-41.
72. Fine RN, Attie KM, Kuntze J, Brown DF, Kohaut EC. Recombinant human growth hormone in infants and young children with chronic renal insufficiency. Pediatr Nephrol 1995;9:451-7.
73. Van Es A. Growth hormone treatment in short children with chronic renal failure and after renal transplantation: combined data from European clinical trials. Acta Paediatr Scand Suppl 1991;379:42-8.
74. Hokken-Koelega AC, Stijnen T, de Jong RC, et al. A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant. Kidney Int Suppl 1996;53:S128-S134.
75. Fine RN. Recombinant human growth hormone in children with chronic renal insufficiency - clinical update: 1995. Kidney Int Suppl 1996; 53:S115-S118.
76. Rosenfeld RG, Attie KM, Frane J, et al. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J Pediatr 1998;132: 319-24.
77. Moore WV, Moore KC, Gifford R, Hollowell JG, Donaldson DL. Long-term treatment with growth hormone of children with short stature and normal growth hormone secretion. J Pediatr 1992;120:702-8.
78. Lesage C, Walker J, Landier F, Chatelain P, Chaussain JL, Bougneres PF. Near normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency. J Pediatr 1991; 119:29-34.
79. Loche S, Cambiaso P, Setzu S, et al. Final height after growth hormone therapy in non-growth-hormone deficient children with short stature. J Pediatr 1994;125:196-200.
80. Hindmarsh PC, Brook CGD. Final height of short normal children treated with growth hormone. Lancet 1996;348:13-6.
81. Bernasconi S, Street ME, Volta C, Mazzardo G. Final height in nongrowth hormone deficient children treated with growth hormone. Clin Endocrinol (Oxf) 1997;47:261-6.
82. Hintz RL, Attie KM, Baptista J, Roche A. Effect of growth hormone treatment on adult height of children with idiopathic short stature. N Engl J Med 1999;340:502-7.
83. Cuttler L, Silvers JB, Singh J, et al. Short stature and growth hormone therapy: a national study of physician recommendation patterns. JAMA 1996;276:531-7.
84. Albertsson-Wikland K. Growth hormone secretion and growth hormone treatment in children with intrauterine growth retardation. Acta Paediatr Scand Suppl 1989;349:35-41.
85. Stanhope R, Ackland F, Hamill G, Clayton J, Jones J, Preece MA. Physiological growth hormone secretion and response to growth hormone treatment in children with short stature and intrauterine growth retardation. Acta Paediatr Scand Suppl 1989;349:47-52.
86. Stanhope R, Preece MA, Hamill G. Does growth hormone treatment improve final height attainment of children with intrauterine growth retardation? Arch Dis Child 1991;66:1180-3.
87. de Zegher F, Maes M, Gargosky SE, et al. High-dose growth hormone treatment of short children born small for gestational age. J Clin Endocrinol Metab 1996;81:1887-92.
88. Bridges NA, Brook CGD. Growth hormone in skeletal dysplasia. Horm Res 1994;42:231-4.
89. Torrado C, Bastian W, Wisniewski KE, Castells S. Treatment of children with Down syndrome and growth retardation with recombinant human growth hormone. J Pediatr 1991;119:478-83.
90. Romano AA, Blethen SL, Dana K, Noto RA. Growth hormone treatment in Noonan syndrome: the National Cooperative Growth Study experience. J Pediatr 1996;128:S18-S21.
91. Lindgren AC, Hagenas L, Muller J, et al. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. Acta Paediatr Suppl 1997;423:60-2.
92. Rotenstein D, Reigel DK, Flom LL. Growth hormone treatment accelerates growth of children with neural tube defects. J Pediatr 1989;115: 417-20.
93. Seikaly MG, Brown R, Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics 1997;100:879-84.
94. Hardin DS, Sy JP. Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience. J Pediatr 1997;131:S65-S69.
95. Blethen SL, MacGillivray MH. A risk-benefit assessment of growth hormone use in children. Drug Saf 1997;17:303-16.
96. Hintz RL. The prismatic case of Creutzfeld-Jakob disease associated with pituitary growth hormone treatment. J Clin Endocrinol Metab 1995; 80:2298-301.
97. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld RG. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996;81:1704-10.
98. Fradkin JE, Mills JL, Schonberger LB, et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA 1993;270:2829-32.
99. Tuffli GA, Johanson A, Rundle AC, Allen DB. Lack of increased risk for extracranial, nooleukemic neoplasms in recipients of recombinant de oxyribonudeic acid growth hormone. J Clin Endocrinol Metab 1995;80: 1416-22.